Cliquer ici pour toutes les publications du CNR-MyRMA en 2017
1368488
EQSSDJFH
2017
items
1
art-libraries-society-of-north-america-arlisna-reviews
0
default
asc
202
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-946454126a207ccae6dc383e1aceaf42%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22EQSSDJFH%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maitre%20et%20al.%22%2C%22parsedDate%22%3A%222017-08-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%26%23x201C%3BAre%20Moxifloxacin%20and%20Levofloxacin%20Equally%20Effective%20to%20Treat%20XDR%20Tuberculosis%3F%26%23x201D%3B%20by%20Thomas%20Maitre%20et%20al.%20%3Ci%3EJournal%20of%20Antimicrobial%20Chemotherapy%3C%5C%2Fi%3E.%2072%2C%20no.%208%20%28August%201%2C%202017%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkx150%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkx150%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Are%20moxifloxacin%20and%20levofloxacin%20equally%20effective%20to%20treat%20XDR%20tuberculosis%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Maitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gr%5Cu00e9goire%22%2C%22lastName%22%3A%22Petitjean%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Najoua%22%2C%22lastName%22%3A%22El%20Helali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Reibel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Chavanet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%20Moxifloxacin%20retains%20partial%20activity%20against%20some%20fluoroquinolone-resistant%20mutants%20of%20Mycobacterium%20tuberculosis.%20Levofloxacin%20is%20presumed%20to%20be%20as%20active%20as%20moxifloxacin%20against%20drug-susceptible%20tuberculosis%20and%20to%20have%20a%20better%20safety%20profile.Objectives%3A%20To%20compare%20the%20in%20vivo%20activity%20of%20levofloxacin%20and%20moxifloxacin%20against%20M.%20tuberculosis%20strains%20with%20various%20levels%20of%20fluoroquinolone%20resistance.Methods%3A%20BALB%5C%2Fc%20mice%20were%20intravenously%20infected%20with%20106M.%20tuberculosis%20H37Rv%20and%20three%20isogenic%20mutants%3A%20GyrA%20A90V%2C%20GyrB%20E540A%20and%20GyrB%20A543V.%20Treatment%20with%2050%20or%20100%5Cu2009mg%5C%2Fkg%20levofloxacin%20and%2060%20or%2066%5Cu2009mg%5C%2Fkg%20moxifloxacin%20was%20given%20orally%20every%206%5Cu2009h%2C%20for%204%5Cu2009weeks.Results%3A%20Levofloxacin%2050%20and%20100%5Cu2009mg%5C%2Fkg%20q6h%20and%20moxifloxacin%2060%20and%2066%5Cu2009mg%5C%2Fkg%20q6h%20generated%20AUCs%20in%20mice%20equivalent%20to%20those%20of%20levofloxacin%20750%20and%201000%5Cu2009mg%5C%2Fday%20and%20moxifloxacin%20400%20and%20800%5Cu2009mg%5C%2Fday%2C%20respectively%2C%20in%20humans.%20Moxifloxacin%2060%20and%2066%5Cu2009mg%5C%2Fkg%20q6h%20had%20bactericidal%20activity%20against%20strain%20H37Rv%20%28MIC%5Cu2009%5Cu2264%5Cu20090.25%5Cu2009mg%5C%2FL%29%20and%20mutants%20GyrB%20E540A%20and%20GyrB%20A543V%20%28MIC%5Cu2009%3D%5Cu20090.5%5Cu2009mg%5C%2FL%29.%20Against%20mutant%20GyrA%20A90V%20%28MIC%5Cu2009%3D%5Cu20092%5Cu2009mg%5C%2FL%29%2C%20moxifloxacin%2060%5Cu2009mg%5C%2Fkg%20q6h%20did%20not%20prevent%20bacillary%20growth%2C%20whereas%2066%5Cu2009mg%5C%2Fkg%20q6h%20had%20bacteriostatic%20activity.%20Levofloxacin%2050%5Cu2009mg%5C%2Fkg%20q6h%20had%20bactericidal%20activity%20against%20H37Rv%20%28MIC%5Cu2009%5Cu2264%5Cu20090.25%5Cu2009mg%5C%2FL%29%20but%20not%20against%20the%20mutant%20strains.%20Levofloxacin%20100%5Cu2009mg%5C%2Fkg%20q6h%20had%20bactericidal%20activity%20against%20H37Rv%20and%20mutants%20GyrB%20E540A%20%28MIC%5Cu2009%3D%5Cu20090.5%5Cu2009mg%5C%2FL%29%20and%20GyrB%20A543V%20%28MIC%3D%5Cu20091%5Cu2009mg%5C%2FL%29%20but%20not%20against%20mutant%20GyrA%20A90V%20%28MIC%5Cu2009%3D%5Cu20094%5Cu2009mg%5C%2FL%29.Conclusions%3A%20All%20mutations%20reduced%20fluoroquinolone%20activity%2C%20even%20those%20classified%20as%20susceptible%20according%20to%20phenotypic%20tests.%20High-dose%20levofloxacin%20is%20less%20effective%20than%20high-dose%20moxifloxacin%20against%20both%20fluoroquinolone-resistant%20and%20-susceptible%20M.%20tuberculosis%20strains%20in%20mice.%22%2C%22date%22%3A%222017%5C%2F08%5C%2F01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fjac%5C%2Fdkx150%22%2C%22ISSN%22%3A%220305-7453%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fjac%5C%2Farticle%5C%2F72%5C%2F8%5C%2F2326%5C%2F3849381%5C%2FAre-moxifloxacin-and-levofloxacin-equally%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-08-02T14%3A41%3A06Z%22%7D%7D%5D%7D
“Are Moxifloxacin and Levofloxacin Equally Effective to Treat XDR Tuberculosis?” by Thomas Maitre et al. Journal of Antimicrobial Chemotherapy. 72, no. 8 (August 1, 2017). https://doi.org/10.1093/jac/dkx150.